Monitoring of TARC and MDC in blood as tool to evaluate disease activity in patients with Hodgkin Disease

Monitoring of TARC and MDC in blood as tool to evaluate disease activity in patients with Hodgkin Disease - Monitoring TARC and MDC in Hodgkin Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30450

Enrollment

Registered

2007-08-01

Start date

2007-06-01

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lymphnode cancer Morbus Hodgkin

Interventions

None listed

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: Children with Morbus Hodgkin (0-18 yrs) included in SKION protocol COG AHOD0031 (METc2004/019)

Exclusion criteria

Exclusion criteria: Pediatric patients not treated on a COG Hodgkins'Disease protocol

Design outcomes

Primary

Measure	Time frame
* Including children with Morbus Hodgkin in the Netherlands in this study will give a larger power to this study and does mean sooner sufficient patient accrual to achieve a reliable result concerning the value of TARC monitoring to determine the disease activity. * In adult patients is has been proved that the TARC level after treatment has a prognostic value. By including children with Morbus Hodgkin we'll be able to determine if this is also the case with children. * By collecting blood during treatment we possibly can get a good idea about the disease activity and efficiency of the treatment.	—

Measure

Time frame

* Including children with Morbus Hodgkin in the Netherlands in this study will give a larger power to this study and does mean sooner sufficient patient accrual to achieve a reliable result concerning the value of TARC monitoring to determine the disease activity. * In adult patients is has been proved that the TARC level after treatment has a prognostic value. By including children with Morbus Hodgkin we'll be able to determine if this is also the case with children. * By collecting blood during treatment we possibly can get a good idea about the disease activity and efficiency of the treatment.

—

Secondary

Measure	Time frame
If the sensivity of increased TARC and MDC serum levels is hight and patients with consistent low TARC and MDC levels are free from failure, measurement of TARC and MDC could replace expensive CT and PET scans.	—

Countries

Netherlands

Outcome results